Danaher partners with the university of pennsylvania's center for cellular immunotherapies to address manufacturing challenges impacting the uptake of cell therapies

Washington , march 7, 2023 /prnewswire/ -- danaher corporation (nyse: dhr), a global science and technology innovator, today announced a strategic partnership with the university of pennsylvania (penn) focusing on cell therapy innovation. the multi-year partnership aims to develop new technologies that will improve the consistency of clinical outcomes for patients and overcome manufacturing bottlenecks in the delivery of next generation engineered cell products.
DHR Ratings Summary
DHR Quant Ranking